{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:20:52Z","timestamp":1786771252335,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The Norman Beischer Research Foundation and the Grollo-Ruzzene Foundation"},{"name":"NHMRC Senior Principal Research Fellow","award":["1135843"],"award-info":[{"award-number":["1135843"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Can serum anti-M\u00fcllerian hormone (AMH) replace polycystic ovary morphology (PCOM) determined by ultrasound as a diagnostic component of polycystic ovary syndrome (PCOS)?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Despite good correlations between serum AMH and PCOM, the use of a high serum AMH as a proxy for PCOM resulted in the reclassification of PCOS in 5% of study participants, with the main effect being more women identified, although some women previously classified as having PCOS were no longer classified as such.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>AMH has been proposed as an alternative to PCOM as a diagnostic component of PCOS. Previous studies are limited by poorly defining PCOS, use of infertile women as comparators, measurement of hormones by immunoassay that lack precision in the female range, low-resolution ovarian ultrasound and inconsistent handling and storage of serum samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>This is an Australian cross-sectional study of 163 non-healthcare-seeking women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Serum AMH was measured by both the Ansh picoAMH assay and the Beckman Coulter Access 2 (BA2) assay, in parallel with androgens measured by liquid chromatography\u2013tandem mass spectrometry, in blood samples of women, not pregnant, breast feeding or using systemic steroids, who also underwent high-resolution ovarian ultrasound. PCOS was determined by the Rotterdam criteria with PCOM defined by the Androgen Excess-PCOS Taskforce recommendation of \u226525 follicles in at least one ovary. Cut-off serum concentrations that best identified women as having PCOM were identified by receiver operator characteristic (ROC) curves.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>A total of 163 women, mean (SD) age 32.5 (5.5) years, who provided a blood sample and had both ovaries visualized on ultrasound were included in the analysis. Women with isolated PCOM had higher median (range) Ansh AMH and BA2 AMH concentrations than those with no PCOS characteristics [56.9 pmol\/l (34.6, 104.2) versus 18.7 (3.2, 50.9), P = 0.002 and 38.5 pmol\/l (22.2, 100.2) versus 16.7 (3.5, 38.9), P = 0.002, respectively]. An AMH \u2265 44.0 pmol\/l, suggested by the ROC curve, identified 80.6% of women with PCOM, falsely identified 15.2% of women without PCOM as having PCOS and had a positive predictive value of 55.6%. The negative predictive value was 94.9%. An AMH BA2 assay cut-off of \u226533.2 pmol\/l provided a sensitivity of 80.6%, a specificity of 79.5% and a positive predictive value for PCOM of 48.1%. The negative predictive value was 94.6% for PCOM. When serum AMH was used in the place of PCOM as a diagnostic criterion for PCOS, the Ansh assay resulted in an additional seven women classified as having PCOS and no longer classified one woman as having PCOS. For the BA2 assay, eight additional and two fewer women were classified as having PCOS. Overall, both assays resulted in six more women being classified as having PCOS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>Women with functional hypogonadotrophic hypogonadism were not excluded and may have been misclassified as having an oligo-amenorrhoea-PCOM phenotype. As study participants were predominantly Caucasian\/White, our findings cannot be generalized to women of other ethnicities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Although serum AMH reflects the number of developing ovarian follicles, the absolute values vary between assays and specific reference ranges for individual assays are required. Irrespective of the assay used, replacing PCOM with serum AMH to diagnose PCOS in a community-based sample altered the number of women classified as having or not having PCOS. Consequently, although overall the risk of women being identified as having PCOS would be increased, some women would no longer be classified as having this condition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>The study was supported by the Norman Beischer Research Foundation and the Grollo-Ruzzene Foundation. S.R.D. is an NHMRC Senior Principal Research Fellow (Grant No. 1135843). S.R.D. reports unrelated support that includes grants from the NHMRC Australia, personal fees for educational activities from Besins Healthcare, Abbott Chile, BioFemme and Pfizer Australia, personal Advisory Board\/consultancy fees from Theramex, Abbott Laboratories, Astellas, Mayne Pharmaceuticals, Roche Diagnostics, Lawley Pharmaceuticals and Que Oncology and has received institutional grant funding from Que Oncology and Ovoca research. The other authors declare no conflicts of interest.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deab232","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:04:30Z","timestamp":1634043870000},"page":"109-118","source":"Crossref","is-referenced-by-count":26,"title":["Substituting serum anti-M\u00fcllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study"],"prefix":"10.1093","volume":"37","author":[{"given":"Robin J","family":"Bell","sequence":"first","affiliation":[{"name":"Women\u2019s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakibul M","family":"Islam","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A","family":"Skiba","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilinie","family":"Herbert","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Martinez Garcia","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"Department of Endocrinology, Division of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-0415","authenticated-orcid":false,"given":"Susan R","family":"Davis","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"2022010517004598400_deab232-B1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"2022010517004598400_deab232-B2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10815-019-01622-7","article-title":"The role of anti-M\u00fcllerian hormone (AMH) in ovarian disease and infertility","volume":"37","author":"Bedenk","year":"2020","journal-title":"J Assist Reprod Genet"},{"key":"2022010517004598400_deab232-B3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/cen.14458","article-title":"Differing performance of two assays for the measurement of anti-Mullerian hormone in premenopausal women: a cross-sectional study","volume":"95","author":"Bell","year":"2021","journal-title":"Clin Endocrinol"},{"key":"2022010517004598400_deab232-B4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ajo.12647","article-title":"Elevated anti-Mullerian hormone in lean women may not indicate polycystic ovarian syndrome","volume":"57","author":"Bradbury","year":"2017","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2022010517004598400_deab232-B5","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1471-0528.2006.01008.x","article-title":"PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors","volume":"113","author":"Broekmans","year":"2006","journal-title":"BJOG"},{"key":"2022010517004598400_deab232-B6","doi-asserted-by":"crossref","first-page":"e3688","DOI":"10.1210\/clinem\/dgz264","article-title":"Screening for androgen excess in women: accuracy of self-reported excess body hair growth and menstrual dysfunction","volume":"105","author":"Chan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/humrep\/dex044","article-title":"High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"32","author":"Cooney","year":"2017","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/humrep\/dex029","article-title":"Influence of the disease label \u2018polycystic ovary syndrome\u2019 on intention to have an ultrasound and psychosocial outcomes: a randomised online study in young women","volume":"32","author":"Copp","year":"2017","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/humrep\/deaa005","article-title":"Clinicians\u2019 perspectives on diagnosing polycystic ovary syndrome in Australia: a qualitative study","volume":"35","author":"Copp","year":"2020","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B10","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1093\/humrep\/deu242","article-title":"Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles","volume":"29","author":"Dewailly","year":"2014","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fendo.2020.00641","article-title":"Role of anti-Mullerian hormone in the pathogenesis of polycystic ovary syndrome","volume":"11","author":"Dewailly","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022010517004598400_deab232-B12","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/humrep\/der297","article-title":"Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries","volume":"26","author":"Dewailly","year":"2011","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B13","doi-asserted-by":"crossref","first-page":"D45","DOI":"10.1530\/EJE-19-0373","article-title":"AMH as the primary marker for fertility","volume":"181","author":"Dewailly","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2022010517004598400_deab232-B14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/humupd\/dmt061","article-title":"Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2022010517004598400_deab232-B15","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1210\/jc.2010-0334","article-title":"Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism","volume":"95","author":"Dewailly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MED.0000000000000445","article-title":"Anti-Mullerian hormone in the pathophysiology and diagnosis of polycystic ovarian syndrome","volume":"25","author":"Dumont","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2022010517004598400_deab232-B17","first-page":"105:e1862\u2013e1871","article-title":"Anti-Mullerian hormone and impending menopause in late reproductive age: the study of women's health across the nation","author":"Finkelstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B18","doi-asserted-by":"crossref","first-page":"e00140","DOI":"10.1016\/j.plabm.2019.e00140","article-title":"Validation of the picoAMH assay on the Dynex DS2 platform","volume":"17","author":"Garnett","year":"2019","journal-title":"Pract Lab Med"},{"key":"2022010517004598400_deab232-B19","first-page":"604","article-title":"Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome","volume":"102","author":"Gibson-Helm","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/humrep\/det033","article-title":"Hypoandrogenism in association with diminished functional ovarian reserve","volume":"28","author":"Gleicher","year":"2013","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1210\/jc.2011-2134","article-title":"Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry","volume":"97","author":"Haring","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B22","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1373\/49.8.1250","article-title":"Immunoassays for testosterone in women: better than a guess?","volume":"49","author":"Herold","year":"2003","journal-title":"Clin Chem"},{"key":"2022010517004598400_deab232-B23","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jc.2010-0202","article-title":"The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance","volume":"95","author":"Johnstone","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1210\/jc.2003-030932","article-title":"Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age","volume":"89","author":"Laven","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.whi.2020.11.003","article-title":"Psychological distress in women living with polycystic ovary syndrome: the role of illness perceptions","volume":"31","author":"Light","year":"2021","journal-title":"Womens Health Issues"},{"key":"2022010517004598400_deab232-B26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0300-595X(86)80021-4","article-title":"1 Adrenal and gonadal androgen secretion in normal females","volume":"15","author":"Longcope","year":"1986","journal-title":"Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12958-016-0143-3","article-title":"Assessment of the access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA","volume":"14","author":"Pearson","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"2022010517004598400_deab232-B28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jc.2005-2076","article-title":"Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome","volume":"91","author":"Pigny","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B29","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1210\/jc.2003-030727","article-title":"Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest","volume":"88","author":"Pigny","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B30","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1210\/jc.2010-1314","article-title":"Toward excellence in testosterone testing: a consensus statement","volume":"95","author":"Rosner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B32","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/humrep\/deab069","article-title":"Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study","volume":"36","author":"Skiba","year":"2021","journal-title":"Hum Reprod"},{"key":"2022010517004598400_deab232-B33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/1753-6405.12868","article-title":"Challenges in recruitment to an epidemiological study of young Australian women: the Grollo-Ruzzene Foundation Young Women's Health Study","volume":"43","author":"Skiba","year":"2019","journal-title":"Aust N Z J Public Health"},{"key":"2022010517004598400_deab232-B34","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1210\/jc.2019-01357","article-title":"Androgens during the reproductive years, what's normal for women?","volume":"104","author":"Skiba","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B35","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1210\/clinem\/dgaa063","article-title":"Distribution of body hair in young Australian women and associations with serum androgen concentrations","volume":"105","author":"Skiba","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010517004598400_deab232-B36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/humupd\/dmy022","article-title":"Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"24","author":"Skiba","year":"2018","journal-title":"Hum Reprod Update"},{"key":"2022010517004598400_deab232-B37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.tem.2019.04.006","article-title":"Anti-Mullerian hormone in PCOS: a review informing international guidelines","volume":"30","author":"Teede","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"2022010517004598400_deab232-B38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.rbmo.2018.10.006","article-title":"Steroid profiles by liquid chromatography-mass spectrometry of matched serum and single dominant ovarian follicular fluid from women undergoing IVF","volume":"38","author":"Walters","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2022010517004598400_deab232-B39","first-page":"377","volume-title":"Polycystic Ovary Syndrome","author":"Zawadski","year":"1992"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/1\/109\/41939373\/deab232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/1\/109\/41939373\/deab232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T17:05:35Z","timestamp":1641402335000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/37\/1\/109\/6422202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,6]]},"published-print":{"date-parts":[[2021,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab232","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,11,6]]}}}